Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 236-195-6 | CAS number: 13223-03-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Start of the experimental phase December 13, 2013, Termination of the in-life phase February 22, 2014.
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 014
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.6 (Skin Sensitisation)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- Study performed before the amendments to Annexes VII and VIII.
Test material
- Test material form:
- other: liquid
- Details on test material:
- - Name of test material (as cited in study report): FlocrylTM MADAM/MECL 75%
- Substance type: Organic
- Physical state: Clear to slightly yellow liquid
- Analytical purity: Monomer concentration 74.9%, 25.1% water
- Impurities (identity and concentrations): Not identified
- Composition of test material, percentage of components: 74.9%
- Purity test date: 04.12.2013
- Lot/batch No.: MADC 1-43-13-03-E
- Expiration date of the lot/batch:
- Stability under test conditions: stable
- Storage condition of test material: At room temperature, not stored together with oxidizing and self-igniting products.
Constituent 1
In vivo test system
Test animals
- Species:
- guinea pig
- Strain:
- Dunkin-Hartley
- Sex:
- male
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, 97633 Sulzfeld, Germany
- Age at study initiation: 5 weeks
- Weight at study initiation: 286 – 315 g (excluding positive control group); Positive control group: 313 – 371 g
- Housing: The animals were kept in pairs in MAKROLON cages (MZK 80/25). Granulated textured wood (Granulat A2, J. BRANDENBURG, 49424 Goldenstedt, Germany) was used as bedding material in the cages. The cages were changed and cleaned twice a week.
- Diet (e.g. ad libitum): Food was offered ad libitum.
- Water (e.g. ad libitum): Tap water (in drinking bottles) was offered ad libitum.
- Acclimation period: At least 5 days.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20°C ± 3°C (maximum range).
- Humidity (%): relative humidity of 55% ± 15% (maximum range)
- Air changes (per hr): 15 to 20 times
- Photoperiod (hrs dark / hrs light): Rooms were lit (about 150 lux at approx. 1.50 m room height) on a 12-hour light/12-hour dark cycle.
IN-LIFE DATES: From: January 29, 2014 To: February 22, 2014
Study design: in vivo (non-LLNA)
Inductionopen allclose all
- Route:
- other: shoulder region, first by intracutaneous application (stage 1) and 7 days later by topical administration (stage 2, exposure time: 48 hours).
- Vehicle:
- other: The test item was diluted in aqua ad iniectabilia for the stage 1 and the challenge or used as supplied for stage 2. Aqua ad iniectabilia Batch nos. 131718161 and 134078161; B. Braun Melsungen, AG, 34212 Melsungen, Germany.
- Concentration / amount:
- stage 1:intracutaneous: 5% solution of FlocrylTM MADAM/MECL 75% in aqua ad iniectabilia
stage 2: topical: undiluted FlocrylTM MADAM/MECL 75%
stage 3: topical: 0.1% solution of FlocrylTM MADAM/MECL 75% in aqua ad iniectabilia
Challengeopen allclose all
- Route:
- other: topically to the flank region (exposure time: 24 hours).
- Vehicle:
- other: The test item was diluted in aqua ad iniectabilia for the stage 1 and the challenge or used as supplied for stage 2. Aqua ad iniectabilia Batch nos. 131718161 and 134078161; B. Braun Melsungen, AG, 34212 Melsungen, Germany.
- Concentration / amount:
- stage 1:intracutaneous: 5% solution of FlocrylTM MADAM/MECL 75% in aqua ad iniectabilia
stage 2: topical: undiluted FlocrylTM MADAM/MECL 75%
stage 3: topical: 0.1% solution of FlocrylTM MADAM/MECL 75% in aqua ad iniectabilia
- No. of animals per dose:
- Vehicle control (aqua ad iniectabilia): 5
FlocrylTM MADAM/MECL 75%: 10
Positive control: 20 - Details on study design:
- RANGE FINDING TESTS: Sixteen animals were used for the preliminary test: 11 animals for the topical administration and 5 animals for the intracutaneous administration. The allocation of different test sites of the animals was alternated in order to minimize site-to-site variations in response.
- Exposure period: 24 hours and 48 hours for the shaved skin, 24 hours for the shaved and depilated skin.
- Concentrations: intracutan: 0.01, 0.1, 0.5, 1, 5, 10% of FlocrylTM MADAM/MECL 75%; topical 100, 75, 50, 25, 10, 5, 1% of FlocrylTM MADAM/MECL 75% (shaved); 0.001, 0.005, 0.01, 0.1, 0.5, 1, 5, 10, 25, 50, 75, 100 % of FlocrylTM MADAM/MECL 75% (shaved and depilated)
MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: 2 (intracutaneous and topical)
- Exposure period: 24 hours and 48 hours
- Test groups: 1
- Control group: 1
- Site: shoulder region
- Frequency of applications: shoulder region, first by intracutaneous application (stage 1) and 7 days later by topical administration (stage 2, exposure time: 48 hours).
- Duration:20 days
- Concentrations: intracutaneous: 5% solution of FlocrylTM MADAM/MECL 75% in aqua ad iniectabilia; topical: undiluted FlocrylTM MADAM/MECL 75%
B. CHALLENGE EXPOSURE
- No. of exposures: 1
- Day(s) of challenge: day 21
- Exposure period: 24 hours
- Test groups: 1
- Control group: 1
- Site: flank region
- Concentrations: 0.1% solution of FlocrylTM MADAM/MECL 75% in aqua ad iniectabilia
- Evaluation (hr after challenge): 48 and 72 hours
OTHER: day 6: 0.5 mL sodium laurylsulphate 10% in Vaseline in order to induce a local irritation - Positive control substance(s):
- yes
- Remarks:
- α-hexyl cinnamic aldehyde
Results and discussion
In vivo (non-LLNA)
Resultsopen allclose all
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 0
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- none
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 0. No with. + reactions: 0.0. Total no. in groups: 5.0. Clinical observations: none.
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 0
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- none
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 0. No with. + reactions: 0.0. Total no. in groups: 5.0. Clinical observations: none.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 0
- No. with + reactions:
- 5
- Total no. in group:
- 5
- Clinical observations:
- discrete or patchy erythema
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 0. No with. + reactions: 5.0. Total no. in groups: 5.0. Clinical observations: discrete or patchy erythema.
- Reading:
- 2nd reading
- Hours after challenge:
- 72
- Group:
- negative control
- Dose level:
- 0
- No. with + reactions:
- 5
- Total no. in group:
- 5
- Clinical observations:
- discrete or patchy erythema
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 72.0. Group: negative control. Dose level: 0. No with. + reactions: 5.0. Total no. in groups: 5.0. Clinical observations: discrete or patchy erythema.
- Reading:
- rechallenge
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 0
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- none
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 48.0. Group: negative control. Dose level: 0. No with. + reactions: 0.0. Total no. in groups: 5.0. Clinical observations: none.
- Reading:
- rechallenge
- Hours after challenge:
- 72
- Group:
- negative control
- Dose level:
- 0
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- none
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 72.0. Group: negative control. Dose level: 0. No with. + reactions: 0.0. Total no. in groups: 5.0. Clinical observations: none.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 5%
- No. with + reactions:
- 10
- Total no. in group:
- 10
- Clinical observations:
- discrete or patchy erythema
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 5%. No with. + reactions: 10.0. Total no. in groups: 10.0. Clinical observations: discrete or patchy erythema.
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 5%
- No. with + reactions:
- 10
- Total no. in group:
- 10
- Clinical observations:
- discrete or patchy erythema
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 48.0. Group: test group. Dose level: 5%. No with. + reactions: 10.0. Total no. in groups: 10.0. Clinical observations: discrete or patchy erythema.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- undiluted
- No. with + reactions:
- 10
- Total no. in group:
- 10
- Clinical observations:
- moderate or confluent erythema or intense erythema and swelling
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: undiluted. No with. + reactions: 10.0. Total no. in groups: 10.0. Clinical observations: moderate or confluent erythema or intense erythema and swelling.
- Reading:
- 2nd reading
- Hours after challenge:
- 72
- Group:
- test chemical
- Dose level:
- undiluted
- No. with + reactions:
- 10
- Total no. in group:
- 10
- Clinical observations:
- a moderate and confluent erythema or intense erythema and swelling
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 72.0. Group: test group. Dose level: undiluted. No with. + reactions: 10.0. Total no. in groups: 10.0. Clinical observations: a moderate and confluent erythema or intense erythema and swelling.
- Reading:
- rechallenge
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 0.1%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- none
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 48.0. Group: test group. Dose level: 0.1%. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: none.
- Reading:
- rechallenge
- Hours after challenge:
- 72
- Group:
- test chemical
- Dose level:
- 0.1%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- none
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 72.0. Group: test group. Dose level: 0.1%. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: none.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 10%
- No. with + reactions:
- 20
- Total no. in group:
- 20
- Clinical observations:
- discrete or patchy erythema
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: positive control. Dose level: 10%. No with. + reactions: 20.0. Total no. in groups: 20.0. Clinical observations: discrete or patchy erythema.
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 10%
- No. with + reactions:
- 20
- Total no. in group:
- 20
- Clinical observations:
- discrete or patchy erythema
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 48.0. Group: positive control. Dose level: 10%. No with. + reactions: 20.0. Total no. in groups: 20.0. Clinical observations: discrete or patchy erythema.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 100%
- No. with + reactions:
- 20
- Total no. in group:
- 20
- Clinical observations:
- moderate and confluent erythema
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: positive control. Dose level: 100%. No with. + reactions: 20.0. Total no. in groups: 20.0. Clinical observations: moderate and confluent erythema.
- Reading:
- 2nd reading
- Hours after challenge:
- 72
- Group:
- positive control
- Dose level:
- 100%
- No. with + reactions:
- 20
- Total no. in group:
- 20
- Clinical observations:
- discrete or patchy erythema
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 72.0. Group: positive control. Dose level: 100%. No with. + reactions: 20.0. Total no. in groups: 20.0. Clinical observations: discrete or patchy erythema.
- Reading:
- rechallenge
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 0.01%
- No. with + reactions:
- 20
- Total no. in group:
- 20
- Clinical observations:
- discrete or patchy erythema or moderate and confluent erythema
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 48.0. Group: positive control. Dose level: 0.01%. No with. + reactions: 20.0. Total no. in groups: 20.0. Clinical observations: discrete or patchy erythema or moderate and confluent erythema.
- Reading:
- rechallenge
- Hours after challenge:
- 72
- Group:
- positive control
- Dose level:
- 0.01%
- No. with + reactions:
- 13
- Total no. in group:
- 20
- Clinical observations:
- discrete or patchy erythema
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 72.0. Group: positive control. Dose level: 0.01%. No with. + reactions: 13.0. Total no. in groups: 20.0. Clinical observations: discrete or patchy erythema.
Any other information on results incl. tables
Behaviour of the animals remained unchanged.
Applicant's summary and conclusion
- Interpretation of results:
- not sensitising
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The challenge with 2 mL of a 1% solution of Flocryl MADAM / MEC 75% in aqua ad iniectabilia/animal revealed no skin irritation in any animal and, thus, the test item had no sensitising properties.
The vehicle control revealed no skin reactions.
Animals of the same strain treated with α-hexyl cinnamic aldehyde in sesame oil exhibited a sensitising reaction in all animals in form of a moderate and confluent erythema (grade 2).
Under the present test conditions, Flocryl MADAM / MEC 75% in aqua ad iniectabilia/animal revealed no skin irritation in any animal and, thus, the test item had no sensitising properties. was found to be not sensitising to guinea pigs in a test model according to MAGNUSSON and KLIGMAN.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Kuigi ECHA veebilehe paljud osad on sinu keeles olemas, on see leht osaliselt inglise keeles. Lisateave ECHA mitmekeelsuse kohta.
Tere tulemast Euroopa Kemikaaliameti (ECHA) veebilehele! Internet Explorer 7 (ja varasemad versioonid) ei toeta täielikult seda veebilehte. Uuendage oma Internet Exploreri versiooni.
Sellel veebilehel kasutatakse küpsiseid, et tagada lehe parim kasutus.
Lisateave küpsiste kohta.